AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions
-
Published:2021
Issue:
Volume:5
Page:100115
-
ISSN:2590-1125
-
Container-title:Clinical Parkinsonism & Related Disorders
-
language:en
-
Short-container-title:Clinical Parkinsonism & Related Disorders
Author:
Lew Mark F.,
Hauser Robert A.,
Isaacson Stuart H.,
Truong Daniel,
Patel Atul T.ORCID,
Brashear Allison,
Ondo William,
Maisonobe Pascal,
Dashtipour Khashayar,
Bahroo Laxman,
Wietek Stefan
Reference19 articles.
1. Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement;Albanese;J. Neurol.,2015
2. G. Defazio, J. Jankovic, J.L. Giel, S. Papapetropoulos, Descriptive epidemiology of cervical dystonia, Tremor. Other Hyperkinet. Mov. (N Y) 3 (2013) tre-03-193-4374-4372.
3. Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study;Mordin;BMJ Open,2014
4. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology;Simpson;Neurology,2016
5. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study;Truong;Mov. Disord.,2005